Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy | Zendy

AnneMarie Taburet | Zendy; Hélène Sauvageon | Zendy; Beatriz Grinsztejn | Zendy; Alex Assuied | Zendy; Valdilea Veloso | Zendy; José Henrique Pilotto | Zendy; Nathalie De Castro | Zendy; Carine Grondin | Zendy; Catherine Fagard | Zendy; JeanMichel Molina | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy

Author(s) -

AnneMarie Taburet,

Hélène Sauvageon,

Beatriz Grinsztejn,

Alex Assuied,

Valdilea Veloso,

José Henrique Pilotto,

Nathalie De Castro,

Carine Grondin,

Catherine Fagard,

JeanMichel Molina

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ477

Subject(s) - medicine , raltegravir , pharmacokinetics , discontinuation , lamivudine , rifampicin , confidence interval , gastroenterology , integrase inhibitor , pharmacology , viral load , tuberculosis , human immunodeficiency virus (hiv) , virology , antiretroviral therapy , chronic hepatitis , virus , pathology

Rifampicin (RIF) induces UGT1A1, an enzyme involved in raltegravir (RAL) elimination, thereby potentially lowering RAL exposure. We examined the pharmacokinetics of RAL in human immunodeficiency virus (HIV)-infected patients on RIF-based antitubercular therapy in the French National Agency for HIV/AIDS and Viral Hepatitis Research 12 180 Reflate Tuberculosis trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research